Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 3, Randomized, Double blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III IV Melanoma (RELATIVITY 098)
NCT Number:
NCT05002569
Phase:
III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Melanoma, Skin
Study Objectives:
The purpose of this study is to assess relatlimab and nivolumab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
Study Documents
(MUSC NetID required for document access)